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Moyamoya disease is a slowly progressing steno-occlusive condition affecting the cere-
brovasculature. Affecting the terminal internal carotid arteries (ICA) and there branches,
bilaterally, a resulting in a fine vascular network in the base of the brain to allow for com-
pensation of the stenosed vessels. While there is obvious evidence of the involvement of
inflammatory proteins in the condition, this has historically not been acknowledged as a
causal factor. Here we describe the fundamental histopathology, genetics, and signaling
cascades involved in moyamoya and debate whether these factors can be linked as causal
factor for the condition or whether they are simply a secondary result of the ischemia
described in the condition. A particular focus has been placed on the multitude of signaling
cascades linked to the condition as these are viewed as having the greatest therapeu-
tic potential. As such we hope to draw some novel insight into potential diagnostic and
therapeutic inflammatory targets in the condition.
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INTRODUCTION
Moyamoya disease is a slowly progressing steno-occlusive con-
dition affecting the cerebrovasculature. Affecting the terminal
internal carotid arteries (ICA) and there branches, bilaterally, a
resulting in a fine vascular network in the base of the brain to
allow for compensation of the stenosed vessels (1). The most dis-
tinguishing feature of this condition is the progressive stenosis of
the ICA which induced further dilation of the perforating arter-
ies that function as collateral pathways. Moyamoya disease is rare,
with the incidence highest in East Asia of 0.35–0.94 and a preva-
lence of 3.16–10.5 per 100,000 (2, 3). The annual incidence is
reported to be approximately 10% that of Japan (4). A bimodal
age distribution has been observed with the predominant peak
originally occurring at 5 years of age followed by a lower peak at
40 years (3).
There is significant debate over the pathogenesis involved
in moyamoya disease, while there is obvious evidence of the
involvement of inflammatory proteins, this has historically not
been acknowledged as a causal factor in the condition (5). Here
we describe the histopathology, genetics, and signaling cascades
involved in moyamoya and debate whether these factors can be
linked as causal factor for the condition or whether they are sim-
ply a result of the ischemia described in the condition. As such
we hope to draw some novel insight into potential diagnostic and
therapeutic inflammatory targets in the condition.
HISTOPATHOLOGY
The histopathology of moyamoya disease has stirred interest for a
number of years. Stenotic changes occur in the intracranial ICAs
immediately distal to the bifurcation. Progression later involves the
proximal anterior and middle cerebral arteries and on rare occa-
sions the posterior circulation may become involved. In adults,
Weinberg et al. (6) describe a typical pattern of fibrocellular thick-
ening of the tunica intima with excessive proliferation of the
vascular smooth-muscle cells, marked tortuousness of the internal
elastic lamina and attenuation of the tunica media (7). Moyamoya
vessels have fibrin deposits in their walls, fragmented elastic lami-
nae, attenuated media, and microaneurysms (8). Thrombosis as a
result of collapse of the lumen is frequently observed in the vessels
of patients (9).
This particular pathology is considered to be responsible for the
onset of both ischemic and hemorrhagic stroke in these patients.
Interestingly, the consensus view is that at a histological level these
vessels lack inflammatory change, which has been considered to
rule out an inflammatory component to the condition (5). How-
ever, Masuda et al. (10) noted the infiltration of macrophages and
T cells in non-stenosed areas of the vessels, suggesting that the
microthrombi may be a result of the chronic inflammation rather
than a cause. In either case, the observation of microthrombi is not
specific to moyamoya disease and therefore is unlikely to provide
a complete explanation for its pathogenesis.
Although limited by the number of cases involved, there appears
to be consensual evidence of inflammation in moyamoya. The lack
of animal models makes it difficult to ascertain whether these find-
ings contribute to the induction of the condition. Nevertheless,
with growing evidence that inflammation is present in the vessel
walls the debate of whether this process induces or results from
moyamoya may be somewhat academic. The important factor is
that there is reversible process in the vessels contributing to steno-
sis and as such significant questions have to be raise about whether
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anti-inflammatory agents could play a role in the treatment of the
condition.
GENETICS
Moyamoya disease has a high familial occurrence accounting for
up to 15% of affected patients (11). The female to male ratio
in familial moyamoya disease is 5.0, which is much higher than
that in sporadic cases (1.6). The mean age at onset of familial
moyamoya disease (11.8 years) is significantly lower than that in
sporadic cases (30.0 years). Interestingly, among parent–offspring
pairs, the age at onset of offspring is on average 23 years lower
than of parents, suggesting strong association with anticipation in
familial moyamoya disease (12).
A number of linkage analysis have demonstrate the involve-
ment of inflammatory genes in moyamoya disease. In particular,
Ikeda et al. (13) demonstrated an association with chromosome
3 and specifically the locus responsible for the maintenance of
vascular wall homeostasis. Chromosome 3p a principle site of
proteins involved in multiple signaling cascades most notably
the IL5RA (interleukin-5 receptor alpha), TGFBR2 (transforming
growth factor beta receptor II), THRB (thyroid hormone receptor
beta), RARB (retinoic acid receptor beta), and PPARG (perox-
isome proliferator-activated receptor gamma) are all involved in
intricate signaling pathways which control and regulate angiogenic
and inflammatory pathways.
Similarly, an association with human leukocyte antigens (HLA)
(14) located on chromosome 6, the 6q25 marker was shared by
84% of families in a recent study. HLA has a strong connection with
immune disorders (15). In particular, alterations in gene transcrip-
tion and protein folding have been linked to aberrant expression of
endothelial-leukocyte adhesion molecule-1 (E-selectin or ELAM-
1), vascular cell adhesion molecule-1 (VCAM-1), and intercel-
lular adhesion molecule-1 (ICAM-1) is induced by the inflam-
matory cytokines interleukin-1 beta (IL-1β) and tumor necrosis
factor-alpha (TNF-α) via the activation of the pro-inflammatory
transcription factor nuclear factor kappa b (NF-κB) (16).
It is clear that there is a panopoly of genes activated in moy-
amoya disease which have an inflammatory association. Whether,
these are responsible for induction of the condition or a result
upstream change remains unclear. Very little in moyamoya dis-
ease has been translated into animal models. Most recently, the
discovery of RNF213 as a susceptibility gene has stirred some
interest (17, 18). RNF213 encodes a gene finger protein with an
AAA ATPase domain and is abundantly expressed in spleen and
leukocytes (17). An RNA in situ hybridization analysis of mouse
tissues indicated that mature lymphocytes express higher levels
of Rnf213 mRNA than their immature counterparts (17). Recent
studies have suggested that the postnatal vasculature can form
through vasculogenesis, a process by which endothelial progeni-
tor cell are recruited from the splenic pool and differentiate into
mature endothelial cells (19). Levels of endothelial progenitor cells
in the peripheral blood are increased in moyamoya disease patients
(20). It is postulated that RNF213 may be expressed in splenic
endothelial progenitor cells and mutant RNF213 might dysregu-
late the function of the endothelial progenitor cells (17). However,
further research is necessary to elucidate the role of RNF213 in the
etiology of the condition.
SIGNALING CASCADES
Cellular signaling cascades provide the interface of genetic and
environmental interaction. An understanding of the cellular sig-
naling cascades which are involved in a condition provides a
platform for the identifying both diagnostic and therapeutic tar-
gets. This stems from the understanding that infection may play a
key role in the pathogenesis of moyamoya disease (21).
The aberrant expression of mitogens, adhesion molecules, and
angiogenic factors (22–25) and/or alterations in cellular responses
to growth factors and cytokines demonstrate the involvement of
inflammatory and hematopoietic cascades in vascular cells (26).
This has been postulated to play a crucial role in the development
of moyamoya pathogenesis (10).
VASCULAR ENDOTHELIAL GROWTH FACTOR
Vascular endothelial growth factor is a 45-kD homodimeric, basic
glycoprotein that requires association with heparin in order to
function (27). It plays a central role in pathological vasculogenesis
and vascular permeability in intracranial lesions. Similarly, VEGF
has been shown to promote angiogenesis in the setting of cerebral
ischemia (28). Interestingly, VEGF expression has been observed
to being NF-kappa B dependent in a number of tissues, includ-
ing endothelial cells (29). Furthermore, studies have shown the
upregulation of Prox1 (30) and downregulation of Notch-1 (31)
to have correlating effects on angiogenic processes. This regula-
tion of angiogenesis by a pro-inflammatory transcription factor
has drawn insight into the potential signaling cascades available
for manipulation in moyamoya disease.
Aberrant expression of VEGF is evident around the affect vas-
culature in moyamoya disease. In a small study, Sakamoto et al.
(28) observed a fourfold increase in VEGF expression in patients
with moyamoya disease. More specifically, the VEGF−634G allele
has been identified has having a particularly strong influence on
moyamoya disease and poor collateral vessel formation (32). The
expression of VEGF is not limited to the cerebral vasculature in
moyamoya disease, Takekawa et al. (33), describes the growth fac-
tor in glial cells and Sakamoto et al. (28) in the dura matter.
The authors suggest that this displays evidence of the patho-
logical mechanisms extending beyond the cerebral vasculature.
Nevertheless, this is most likely associated with the induction
of pro-inflammatory cascades as a result of ischemia and a sec-
ondary marker of disease rather than a primary modality for the
pathogenesis.
BASIC FIBROBLAST GROWTH FACTOR
Basic fibroblast growth factor (bFGF) is an 18-kD protein consist-
ing of 146 amino acids (34). The primary role of bFGF involves
the stimulation of mesodermal and neuroectodermal proliferation
(35), additionally it has been shown to induce growth of vascular
smooth muscle and, when combined with VEGF, can play a leading
role in angiogenesis (36). A hypothesized pathway for this is via
the upregulation of circulating chemokines (37). In particular, the
chemokine-mediated regulation of angiogenesis is highly sophis-
ticated and fine tuned, and involves pro-angiogenic chemokines,
for instance, CXCL8/IL8 interacting with the CXCR2 receptor,
and anti-angiogenic (i.e., angiostatic) chemokines, for instance,
CXCL10/IP10 interacting with the CXCR3 receptor (37).
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Basic fibroblast growth factor has been observed to be aber-
rantly expressed in the colony-stimulating factor (CSF) of moy-
amoya disease patients (24, 38), with both groups agreeing that the
expression levels were 10-fold higher in moyamoya disease. Addi-
tionally, bFGF was also observed in the thickened tunica media,
assisting suggestions that the upregulation of the molecule is asso-
ciated with both stenotic and angiogenic processes (38). Yan et al.
(39) describes separate in vitro and in vivo models of bFGF pro-
moting neovascularization. In relation to corneal wound healing,
a comparison with recombinant human epidermal growth factor
(rhEGF) led the others to believe that the effects of bFGF were too
strong to promote controlled healing (39). Interestingly, the inhi-
bition of bFGF has been demonstrated to inhibit the proliferation
and migration of endothelial cells (40). As such it could be viewed
that bFGF plays and intricate role in the development of vessel
proliferation and endothelial cell recruitment. With this in mind
there may be future scope to incorporate the molecule into new
therapeutic strategies.
HEPATOCYTE GROWTH FACTOR
Hepatocyte growth factor (HGF) is one of the largest disulfide-
linked cytokines, and in humans the protein is synthesized as a
single-stranded 728 amino acid protein (6). The proteolytic acti-
vation of HGF involves the release of a 31 amino acid N-terminal
signal peptide which has been observed to potentiate the growth
of various epithelial, endothelial, and mesenchymal cells (41).
In various injury and disease models, the HGF-Met pathway
plays a critical role in acute tissue protection and regeneration,
and in providing less susceptibility to chronic inflammation and
fibrosis (42).
Nanba et al. (43) demonstrated a twofold increase in both
HGF and its receptor c-Met expression in the tunica media and
intima of patients with moyamoya disease compared to control
groups with cervical spondylosis and unilateral internal carotid
artery occlusion. From this it was postulated that the upreg-
ulation of HGF plays a role in the pathogenesis of intimal
thickening and vascular smooth-muscle cell migration. Addi-
tionally, hypoxia inducible factor-1α, which promotes smooth-
muscle cell proliferation in the presence of bFGF and HGF, is
present in elevated levels in moyamoya disease (44). In addi-
tion to HGF being densely found in the carotid fork, its CSF
level is markedly elevated in moyamoya disease, suggesting that
HGF may be a key protein for pathogenesis of moyamoya disease
(43). From this information it is apparent that the inhibition of
HGF in the carotid vasculature would be advantageous. Whether
it plays a role in the initiation of other cascades remains uncer-
tain however, it is clear that inhibiting HGF expression in the
carotids could prove beneficial in the treatment of moyamoya
disease.
TRANSFORMING GROWTH FACTOR-β1
Transforming growth factor-β1 (TGFβ1) in its original form
is a 390 amino acid peptide that is proteolytically activated
to form the active 112 amino acid monomeric form of the
active TGFβ1 homodimer (6). Implicated in a variety of cel-
lular processes including cell growth, proliferation, and differ-
entiation (45), TGFβ1 is involved in the expression cascade of
various connective-tissue genes at normal physiological concen-
trations. Nevertheless, when it is aberrantly upregulated it has been
postulated to contribute to pathological angiogenesis (46).
The upregulation of TGFβ1 has been implicated in the patho-
genesis of moyamoya disease. Specifically, Hojo et al. (46) demon-
strated a threefold increase in serum TGFβ1 levels of moyamoya
disease patients compared to controls. Additionally, similar studies
on atherosclerosis failed to demonstrate significant deviation from
control results (47), speculating that TGFβ1 may play a significant
role in the neovascularization process (46). Furthermore, TGFβ1
has been associated with increased production of elastin synthase,
which is involved in intimal cell proliferation, a hallmark of moy-
amoya disease (25). Interestingly, a recent study by Liu et al. (48)
failed to observe any aberrant gene expression when sequencing
the first exon of TGFβ1 in both European and Japanese cohorts.
In particular, they failed to demonstrate the previous association
of rs1800471 and tendency toward significance of rs1800470 sug-
gesting that although TGFβ1 may be aberrantly expressed at the
protein level this may be a result of stimulation from upstream
mediators rather than mutations within the gene itself (48).
GRANULOCYTE COLONY-STIMULATING FACTOR
Granulocyte colony-stimulating factor (G-CSF), key mediator of
the acute inflammatory reaction exists as a 174 amino acid mature
protein weighing 19.6 kD (49). It is a glycoprotein, growth factor,
and cytokine, the main function of which is the stimulation of pro-
liferation, survival, and maturation of neutrophil precursors and
mature neutrophils. The regulation of such properties by G-CSF is
via the activation of Janus kinase (JAK)/signal transducer and acti-
vator of transcription (STAT) and Ras/mitogen-activated protein
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/protein
kinase B (Akt) signal transduction pathways (50). The activa-
tion of NF-kappa B is also heavily linked to the regulation of the
cytokine (51).
In moyamoya disease elevated concentrations of G-CSF have
been demonstrated to be as high as 1.5-fold more than controls
(52). Interestingly, expression of CSF was also observed within
atherosclerotic plaques (53). As such it is unlikely to be specific to
moyamoya disease however, would appear to contribute to vessel
narrowing because of its action on cell recruitment (53). How-
ever, the extent to which G-CSF is involved in the pathogenesis of
moyamoya disease has yet to be determined.
EXTRACELLULAR MARKERS
Individually, prostaglandin E2 (25), IL-1β (25), and cellular
retinoic acid binding protein 1 (54) have been shown to be
increased in concentration. Additionally, several soluble endothe-
lial adhesion molecules have been observed in the CSF of patients
with moyamoya disease. Specifically, the observation of VCAM-1,
ICAM-1, and E-selectin (23).
Additionally, levels of MMP-9 were found to be significantly
raised in moyamoya disease comparison to healthy controls (55).
MMP-9 (gelatinase B) attenuates the impenetrability of the blood-
brain barrier by interrupting the endothelial basal lamina and as
a consequence plays a role in cerebral ischemia, and the forma-
tion and rupture of cerebral aneurysms, as well as other CNS
pathologies.
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CONCLUSION
There is significant debate over the pathogenesis involved in moy-
amoya disease. While there is obvious evidence of the involvement
of inflammatory proteins, this has historically not been acknowl-
edged as a causal factor in the condition (5). Here we have reviewed
the histopathology, genetics, and signaling cascades involved in
moyamoya disease identifying a number of key targets which
may assist in the treatment of the condition. Although it remains
uncertain to whether these factors play a role in the initiation of
signaling cascades or if they are downstream mediators the clearly
play significant roles in the pathogenesis. With this in mind it is
important to consider these as important targets in the treatment
of moyamoya disease.
In particular, significant research will have to be undertaken
to fully understand the effects of each signaling molecule and at
which part of the pathway they act. The distinct creation of moy-
amoya vessels is almost certainly secondary to the initial stenosis
observed in the ICA. By preventing this it is possible that the subse-
quent creation of fragile vessels could be avoided. From this review
it is apparent that bFGF and G-CSF play a role in this process
and could both demonstrate potential diagnostic and therapeutic
relevance in the future.
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